{"date":"2026-02-05","count":13,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6857-2026-02-05-1729-tmcco0","company_id":"6857","company":"宏碁智醫","market":"興櫃","industry":"生技醫療","date":"2026-02-05","time":"17:29:33","subject":"公告本公司取得經濟部產業發展署出具「係屬科技事業」之意見書","clause":"第44款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：宏碁智醫（6857），2026-02-05 17:29，「公告本公司取得經濟部產業發展署出具「係屬科技事業」之意見書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-02-05-1728-agolpz","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-02-05","time":"17:28:25","subject":"代子公司八億實業(股)公司公告115年第二次股東臨時會決議解除新任董事競業禁止限制案","clause":"第21款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-02-05 17:28，「代子公司八億實業(股)公司公告115年第二次股東臨時會決議解除新任董事競業禁止限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-02-05-1727-5lz6mt","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-02-05","time":"17:27:48","subject":"代子公司八億實業(股)公司公告115年第二次股東臨時會董事當選名單暨董事變動達三分之一","clause":"第6款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-02-05 17:27，「代子公司八億實業(股)公司公告115年第二次股東臨時會董事當選名單暨董事變動達三分之一」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4131-2026-02-05-1726-8x115r","company_id":"4131","company":"浩泰","market":"上櫃","industry":"生技醫療","date":"2026-02-05","time":"17:26:37","subject":"代子公司八億實業(股)公司公告115年第二次股東臨時會重要決議事項","clause":"第18款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：浩泰（4131），2026-02-05 17:26，「代子公司八億實業(股)公司公告115年第二次股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4737-2026-02-05-1720-1l248wr","company_id":"4737","company":"華廣","market":"上市","industry":"生技醫療","date":"2026-02-05","time":"17:20:53","subject":"公告本公司114年現金增資收足股款暨增資基準日","clause":"第51款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：華廣（4737），2026-02-05 17:20，「公告本公司114年現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6815-2026-02-05-1715-3za6en","company_id":"6815","company":"晶鑽生醫","market":"興櫃","industry":"生技醫療","date":"2026-02-05","time":"17:15:00","subject":"更正本公司114年12月營收及累計營收資訊","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：晶鑽生醫（6815），2026-02-05 17:15，「更正本公司114年12月營收及累計營收資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1707-2026-02-05-1637-a4gv9q","company_id":"1707","company":"葡萄王","market":"上市","industry":"生技醫療","date":"2026-02-05","time":"16:37:11","subject":"代本公司重要子公司葡眾企業股份有限公司公告董事會決議對關係人之捐贈事宜","clause":"第43款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：葡萄王（1707），2026-02-05 16:37，「代本公司重要子公司葡眾企業股份有限公司公告董事會決議對關係人之捐贈事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1707-2026-02-05-1635-uxv4g8","company_id":"1707","company":"葡萄王","market":"上市","industry":"生技醫療","date":"2026-02-05","time":"16:35:33","subject":"代本公司重要子公司葡眾企業股份有限公司公告董事會決議召開115年股東常會","clause":"第17款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：葡萄王（1707），2026-02-05 16:35，「代本公司重要子公司葡眾企業股份有限公司公告董事會決議召開115年股東常會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1707-2026-02-05-1634-1vluozb","company_id":"1707","company":"葡萄王","market":"上市","industry":"生技醫療","date":"2026-02-05","time":"16:34:00","subject":"代本公司重要子公司葡眾企業股份有限公司公告董事會決議股利分派","clause":"第14款","fact_date":"2026-02-05","cite_as":"公開資訊觀測站重大訊息：葡萄王（1707），2026-02-05 16:34，「代本公司重要子公司葡眾企業股份有限公司公告董事會決議股利分派」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6586-2026-02-05-1613-1jhewlf","company_id":"6586","company":"醣基","market":"興櫃","industry":"生技醫療","date":"2026-02-05","time":"16:13:48","subject":"公告本公司公司治理主管異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：醣基（6586），2026-02-05 16:13，「公告本公司公司治理主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2026-02-05-1537-lud0my","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2026-02-05","time":"15:37:13","subject":"更正本公司114年第二季合併財務報告董事會召集通知日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2026-02-05 15:37，「更正本公司114年第二季合併財務報告董事會召集通知日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2026-02-05-1532-q8ydiy","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2026-02-05","time":"15:32:35","subject":"本公司公告APC101已經美國FDA通過核准進行第二b/三期臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2026-02-05 15:32，「本公司公告APC101已經美國FDA通過核准進行第二b/三期臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6610-2026-02-05-0505-7423ho","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2026-02-05","time":"05:05:50","subject":"公告本公司用於治療單純型遺傳性表皮分解性水皰症(EBS)之新藥AC-203第二/三期人體臨床試驗期中分析，經數據安全監測委員會(DSMB)建議，得依原計畫續行，完成80名受試者收案。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2026-02-05 05:05，「公告本公司用於治療單純型遺傳性表皮分解性水皰症(EBS)之新藥AC-203第二/三期人體臨床試驗期中分析，經數據安全監測」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}